Fulltext

Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer

Butt J 1 , Jenab M 2 , Pawlita M 1 , Overvad K 3 , Tjonneland A 4 , Olsen A 4 Show all authors , Boutron-Ruault MC 5 , Carbonnel F 5 , Mancini FR 5 , Kaaks R 6 , Kühn T 6 , Boeing H 7 , Trichopoulou A 8 , Karakatsani A 8 , Palli D 9 , Pala VM 10 , Tumino R 11 , Sacerdote C 12 , Panico S 13 , Bueno-de-Mesquita B 14 , van Gils CH 15 , Vermeulen RCH 15 , Weiderpass E 16 , Quirós JR 17 , Duell EJ 18 , Sánchez MJ 19 , Dorronsoro M 20 , Huerta JM 21 , Ardanaz E 21 , Van Guelpen B 22 , Harlid S 22 , Perez-Cornago A 23 , Gunter MJ 2 , Murphy N 2 , Freisling H 2 , Aune D 24 , Waterboer T 1 , Hughes DJ 25

Affiliations 

  • 1 Infection and Cancer Epidemiology, Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 2 Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France
  • 3 Department of Cardiology and Department of Clinical Epidemiology, Aarhus Hospital, Aalborg, Denmark
  • 4 Danish Cancer Society Research Center, Copenhagen, Denmark
  • 5 CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
  • 6 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 7 Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany
  • 8 Hellenic Health Foundation, Athens, Greece
  • 9 Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy
  • 10 Epidemiology and Prevention Unit, Department of Preventive & Predictive Medicine, Fondazione Istituto Nazionale dei Tumori, Milan, Italy
  • 11 Cancer Registry and Histopathology Department, "Civic - M.P. Arezzo" Hospital, ASP Ragusa, Italy
  • 12 Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy
  • 13 Dipartimento die Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
  • 14 Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
  • 15 Julius Center for Health Sciences and Primary Care, Cancer Epidemiology, University Medical Center Utrecht, the Netherlands
  • 16 Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
  • 17 EPIC Asturias, Public Health Directorate Asturias, Oviedo, Spain
  • 18 Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
  • 19 Escuela Andaluza de Salud pública, Instituto de Investigacíon ibs.Granada, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
  • 20 Public Health Direction and Biodonostia-Ciberesp, Basque Regional Health Department, San Sebastian, Spain
  • 21 CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
  • 22 Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
  • 23 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  • 24 Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom
  • 25 Cancer Biology and Therapeutics Group, UCD Conway Institute, University College Dublin, Dublin, Ireland. david.hughes@ucd.ie
Cancer Epidemiol Biomarkers Prev, 2019 Sep;28(9):1552-1555.
PMID: 31481495 DOI: 10.1158/1055-9965.EPI-19-0313

Abstract

BACKGROUND: There is a lack of prospective data on the potential association of Fusobacterium nucleatum (F. nucleatum) and colorectal cancer risk. In this study, we assessed whether antibody responses to F. nucleatum are associated with colorectal cancer risk in prediagnostic serum samples in the European Prospective Investigation into Nutrition and Cancer (EPIC) cohort.

METHODS: We applied a multiplex serology assay to simultaneously measure antibody responses to 11 F. nucleatum antigens in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CI).

RESULTS: We observed neither a statistically significant colorectal cancer risk association for antibodies to individual F. nucleatum proteins nor for combined positivity to any of the 11 proteins (OR, 0.81; 95% CI, 0.62-1.06).

CONCLUSIONS: Antibody responses to F. nucleatum proteins in prediagnostic serum samples from a subset of colorectal cancer cases and matched controls within the EPIC study were not associated with colorectal cancer risk.

IMPACT: Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications